This observational study will evaluate the dosage patterns, safety and efficacy of RoActemra/Actemra (tocilizumab) in clinical practice in patients with moderate to severe rheumatoid arthritis who have not responded or are intolerant to at least one disease-modifying antirheumatic drug (DMARD) or TNF inhibitor. Data will be collected from each patients for 12 months.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01338545?cond=%22Arthritis%22&lup_s=10/31/2013&lup_d=30
